Pharmaceutical Titans Lose Bid to Stop Medicare From Bargaining Down Prescription Costs

Pharmaceutical companies trying to block Medicare price bargaining suffered another setback Monday after the Supreme Court declined to hear constitutional claims targeting one of the most consequential healthcare measures enacted in recent years.

Lower court decisions supporting the program will remain intact after the justices rejected appeals brought by several major corporations, according to the Associated Press. Congress created the system through the Inflation Reduction Act signed into law in 2022, giving Medicare power to bargain over some of the country’s costliest prescription treatments.

Businesses involved in the courtroom dispute included Merck & Co., Bristol Myers Squibb, AstraZeneca, Novo Nordisk, Novartis, and subsidiaries connected to Johnson & Johnson. Industry leaders argued the framework violated constitutional protections by forcing participation in agreements they believed reduced influence over product valuation and long term earnings.

Federal judges repeatedly dismissed those arguments during earlier stages of the case. Courts concluded participation in Medicare remains voluntary and ruled Washington has broad discretion to manage spending within the nation’s largest public insurance network.

Bargaining involving an initial group of treatments has already concluded. Selected products address conditions including diabetes, autoimmune disorders, blood clots, heart disease, and several forms of cancer. Officials expect revised prices connected to the first round of medicines to begin taking effect in 2026.

Backers of the policy argue Medicare finally secured leverage long exercised by private insurers. Administration officials have spent years pointing to higher prescription prices in the United States compared with amounts paid across many other developed nations.

Trade organizations continue warning the policy could eventually reduce investment connected to medical research and experimental therapies. Company executives have argued declining revenue may shape long term decisions involving clinical studies, manufacturing growth, and additional treatment development.

Congress approved the structure after decades of political conflict surrounding prescription expenses for older Americans. Earlier attempts to grant Medicare direct bargaining authority repeatedly stalled despite widespread frustration over rising pharmacy costs.

The Supreme Court offered no explanation for refusing to hear the appeals, following standard practice when petitions are denied without comment. By leaving lower court decisions untouched, the justices cleared the way for federal officials to expand bargaining involving additional treatments during the coming years.

For the healthcare industry, the legal defeat leaves fewer immediate paths for slowing a policy expected to reshape financial influence across one of the country’s most profitable business sectors.